The Beauty Health Company Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
The Beauty Health Company has an operating margin of -20.3%, meaning the company retains $-20 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -32.9% the prior year.
The Beauty Health Company's revenue declined 16% year-over-year, from $398.0M to $334.3M. This contraction results in a growth score of 0/100.
The Beauty Health Company has elevated debt relative to equity (D/E of 10.66), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 7.00, The Beauty Health Company holds $7.00 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
The Beauty Health Company's free cash flow margin of 4.6% results in a low score of 23/100. Capital expenditures of $756K absorb a large share of operating cash flow.
The Beauty Health Company passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, The Beauty Health Company generates $-0.55 in operating cash flow ($16.1M OCF vs -$29.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
The Beauty Health Company earns $-6.5 in operating income for every $1 of interest expense (-$67.8M vs $10.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows The Beauty Health Company (SKIN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
The Beauty Health Company generated $334.3M in revenue in fiscal year 2024. This represents a decrease of 16.0% from the prior year.
The Beauty Health Company's EBITDA was -$38.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.2% from the prior year.
The Beauty Health Company generated $15.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 14.2% from the prior year.
The Beauty Health Company reported -$29.1M in net income in fiscal year 2024. This represents an increase of 70.9% from the prior year.
The Beauty Health Company earned $-0.36 per diluted share (EPS) in fiscal year 2024. This represents an increase of 52.6% from the prior year.
The Beauty Health Company held $370.1M in cash against $552.2M in long-term debt as of fiscal year 2024.
The Beauty Health Company had 125M shares outstanding in fiscal year 2024. This represents an increase of 1.6% from the prior year.
The Beauty Health Company's gross margin was 54.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 15.6 percentage points from the prior year.
The Beauty Health Company's operating margin was -20.3% in fiscal year 2024, reflecting core business profitability. This is up 12.6 percentage points from the prior year.
The Beauty Health Company's net profit margin was -8.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 16.5 percentage points from the prior year.
The Beauty Health Company invested $6.3M in research and development in fiscal year 2024. This represents a decrease of 37.7% from the prior year.
The Beauty Health Company spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
The Beauty Health Company invested $756K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 80.2% from the prior year.
SKIN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.7M-9.6% | $78.2M+12.4% | $69.6M-16.7% | $83.5M-7.8% | $90.6M+11.3% | $81.4M-15.9% | $96.8M-0.6% | $97.4M |
| Cost of Revenue | $25.0M-13.9% | $29.1M+38.5% | $21.0M-32.6% | $31.1M-37.3% | $49.7M+50.3% | $33.0M-35.4% | $51.1M-53.5% | $110.0M |
| Gross Profit | $45.6M-7.1% | $49.1M+1.1% | $48.6M-7.2% | $52.3M+27.9% | $40.9M-15.3% | $48.4M+5.9% | $45.7M+463.9% | -$12.6M |
| R&D Expenses | $1.7M+35.7% | $1.3M+25.4% | $998K-18.3% | $1.2M+5.4% | $1.2M-58.7% | $2.8M-7.8% | $3.0M+65.6% | $1.8M |
| SG&A Expenses | $29.3M+6.5% | $27.5M-18.2% | $33.6M+5.7% | $31.8M+1.1% | $31.4M+8.8% | $28.9M-0.4% | $29.0M-21.6% | $37.0M |
| Operating Income | -$6.2M-131.2% | -$2.7M+77.5% | -$12.0M-68.0% | -$7.2M+67.6% | -$22.1M-30.1% | -$17.0M+7.5% | -$18.4M+77.6% | -$82.1M |
| Interest Expense | $6.3M+52.3% | $4.1M+65.9% | $2.5M+1.4% | $2.5M+0.4% | $2.5M-19.0% | $3.0M-9.8% | $3.4M-2.5% | $3.4M |
| Income Tax | $386K+138.9% | -$993K-211.3% | $892K+164.3% | -$1.4M-293.2% | -$353K+46.4% | -$659K-209.3% | $603K-82.7% | $3.5M |
| Net Income | -$11.0M-156.0% | $19.7M+295.2% | -$10.1M+2.3% | -$10.3M-5213.9% | $202K+129.7% | -$679K+92.8% | -$9.4M+87.3% | -$73.8M |
| EPS (Diluted) | $-0.09-400.0% | $0.03+137.5% | $-0.08-700.0% | $-0.01+90.0% | $-0.100.0% | $-0.10-25.0% | $-0.08+85.7% | $-0.56 |
SKIN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $503.6M-0.8% | $507.6M-24.7% | $673.8M-1.7% | $685.7M-3.7% | $711.8M-15.7% | $844.7M-9.1% | $929.1M-4.5% | $973.1M |
| Current Assets | $308.4M+0.7% | $306.1M-34.8% | $469.4M-1.6% | $477.1M-2.6% | $489.6M-20.4% | $614.8M-11.9% | $698.3M-5.4% | $738.0M |
| Cash & Equivalents | $219.4M+3.5% | $212.0M-43.2% | $373.0M+0.8% | $370.1M+5.9% | $349.5M-21.4% | $444.6M-15.0% | $523.0M-6.5% | $559.4M |
| Inventory | $56.1M-5.1% | $59.2M-9.8% | $65.6M-5.0% | $69.1M-10.4% | $77.1M-19.4% | $95.7M+4.8% | $91.3M+22.0% | $74.9M |
| Accounts Receivable | $22.2M-11.3% | $25.0M+7.7% | $23.3M-15.9% | $27.6M-33.2% | $41.4M-13.1% | $47.7M-12.9% | $54.7M-18.1% | $66.8M |
| Goodwill | $126.5M+0.2% | $126.3M+1.6% | $124.3M+0.6% | $123.5M-1.1% | $124.8M-0.4% | $125.4M-0.4% | $125.8M+0.9% | $124.7M |
| Total Liabilities | $438.0M+1.0% | $433.6M-30.9% | $627.8M-1.0% | $633.9M-1.4% | $642.6M-17.8% | $781.4M-10.2% | $869.7M-1.5% | $883.1M |
| Current Liabilities | $61.9M+4.1% | $59.4M-5.4% | $62.8M-7.8% | $68.2M-9.6% | $75.4M-19.4% | $93.6M-18.6% | $115.0M-8.6% | $125.9M |
| Long-Term Debt | $363.4M+0.1% | $363.1M | N/A | $552.2M | N/A | N/A | N/A | N/A |
| Total Equity | $65.7M-11.3% | $74.0M+60.7% | $46.1M-11.1% | $51.8M-25.1% | $69.2M+9.3% | $63.3M+6.6% | $59.4M-34.0% | $90.0M |
| Retained Earnings | -$509.4M-2.2% | -$498.3M+3.8% | -$518.1M-2.0% | -$508.0M-6.0% | -$479.3M0.0% | -$479.5M-0.1% | -$478.9M-2.0% | -$469.5M |
SKIN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.6M0.0% | $9.6M+222.0% | $3.0M-81.8% | $16.5M+165.6% | $6.2M+136.8% | -$16.9M-226.0% | -$5.2M-128.8% | $18.0M |
| Capital Expenditures | $27K-70.7% | $92K+104.4% | $45K-39.2% | $74K-77.8% | $334K-2.9% | $344K+1128.6% | $28K-83.9% | $174K |
| Free Cash Flow | $9.6M+0.7% | $9.6M+223.8% | $3.0M-82.0% | $16.4M+179.5% | $5.9M+134.1% | -$17.2M-230.9% | -$5.2M-129.2% | $17.8M |
| Investing Cash Flow | -$1.1M+30.2% | -$1.6M-35.5% | -$1.1M-32.8% | -$862K+57.7% | -$2.0M-13.1% | -$1.8M+16.9% | -$2.2M+51.1% | -$4.4M |
| Financing Cash Flow | -$803K+99.5% | -$173.4M-69244.4% | -$250K+67.5% | -$770K+99.2% | -$98.7M-68.5% | -$58.6M-86.9% | -$31.4M-1234.3% | -$2.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $30.2M | N/A |
SKIN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.6%+1.8pp | 62.8%-7.0pp | 69.8%+7.1pp | 62.7%+17.5pp | 45.2%-14.2pp | 59.4%+12.2pp | 47.2%+60.1pp | -12.9% |
| Operating Margin | -8.8%-5.4pp | -3.5%+13.8pp | -17.3%-8.7pp | -8.6%+15.8pp | -24.4%-3.5pp | -20.9%-1.9pp | -19.0%+65.3pp | -84.3% |
| Net Margin | -15.6%-40.8pp | 25.2%+39.7pp | -14.5%-2.1pp | -12.4%-12.6pp | 0.2%+1.1pp | -0.8%+8.9pp | -9.7%+66.1pp | -75.8% |
| Return on Equity | N/A | 26.6% | N/A | N/A | 0.3% | N/A | N/A | N/A |
| Return on Assets | -2.2%-6.1pp | 3.9%+5.4pp | -1.5%+0.0pp | -1.5%-1.5pp | 0.0%+0.1pp | -0.1%+0.9pp | -1.0%+6.6pp | -7.6% |
| Current Ratio | 4.98-0.2 | 5.15-2.3 | 7.47+0.5 | 7.00+0.5 | 6.49-0.1 | 6.57+0.5 | 6.07+0.2 | 5.86 |
| Debt-to-Equity | 5.53+0.6 | 4.91-8.7 | 13.63+3.0 | 10.66+1.4 | 9.29-3.1 | 12.35-2.3 | 14.64+4.8 | 9.82 |
| FCF Margin | 13.6%+1.4pp | 12.2%+8.0pp | 4.2%-15.4pp | 19.6%+13.2pp | 6.5%+27.6pp | -21.1%-15.8pp | -5.4%-23.6pp | 18.3% |
Similar Companies
Frequently Asked Questions
What is The Beauty Health Company's annual revenue?
The Beauty Health Company (SKIN) reported $334.3M in total revenue for fiscal year 2024. This represents a -16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is The Beauty Health Company's revenue growing?
The Beauty Health Company (SKIN) revenue declined by 16% year-over-year, from $398.0M to $334.3M in fiscal year 2024.
Is The Beauty Health Company profitable?
No, The Beauty Health Company (SKIN) reported a net income of -$29.1M in fiscal year 2024, with a net profit margin of -8.7%.
What is The Beauty Health Company's earnings per share (EPS)?
The Beauty Health Company (SKIN) reported diluted earnings per share of $-0.36 for fiscal year 2024. This represents a 52.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is The Beauty Health Company's EBITDA?
The Beauty Health Company (SKIN) had EBITDA of -$38.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does The Beauty Health Company have?
As of fiscal year 2024, The Beauty Health Company (SKIN) had $370.1M in cash and equivalents against $552.2M in long-term debt.
What is The Beauty Health Company's gross margin?
The Beauty Health Company (SKIN) had a gross margin of 54.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is The Beauty Health Company's operating margin?
The Beauty Health Company (SKIN) had an operating margin of -20.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is The Beauty Health Company's net profit margin?
The Beauty Health Company (SKIN) had a net profit margin of -8.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is The Beauty Health Company's free cash flow?
The Beauty Health Company (SKIN) generated $15.4M in free cash flow during fiscal year 2024. This represents a -14.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is The Beauty Health Company's operating cash flow?
The Beauty Health Company (SKIN) generated $16.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are The Beauty Health Company's total assets?
The Beauty Health Company (SKIN) had $685.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are The Beauty Health Company's capital expenditures?
The Beauty Health Company (SKIN) invested $756K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does The Beauty Health Company spend on research and development?
The Beauty Health Company (SKIN) invested $6.3M in research and development during fiscal year 2024.
How many shares does The Beauty Health Company have outstanding?
The Beauty Health Company (SKIN) had 125M shares outstanding as of fiscal year 2024.
What is The Beauty Health Company's current ratio?
The Beauty Health Company (SKIN) had a current ratio of 7.00 as of fiscal year 2024, which is generally considered healthy.
What is The Beauty Health Company's debt-to-equity ratio?
The Beauty Health Company (SKIN) had a debt-to-equity ratio of 10.66 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is The Beauty Health Company's return on assets (ROA)?
The Beauty Health Company (SKIN) had a return on assets of -4.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is The Beauty Health Company's Piotroski F-Score?
The Beauty Health Company (SKIN) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are The Beauty Health Company's earnings high quality?
The Beauty Health Company (SKIN) has an earnings quality ratio of -0.55x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can The Beauty Health Company cover its interest payments?
The Beauty Health Company (SKIN) has an interest coverage ratio of -6.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is The Beauty Health Company?
The Beauty Health Company (SKIN) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.